Sorafenib tosylate suppliers

Sorafenib tosylate

CAS:: 475207-59-1

MF:: C21H16ClF3N4O3.C7H8O3S

MW:: 637.03

Use：: In a stage three randomized clinical study of American and European treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. One group received sorafenib tosylate, while the other received a placebo. Mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. The sorafenib tosylate groups survival period was longer than that of the placebo group, with the risk ratio as 0.72. However, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison. 602 advanced liver cancer patients selected from the USA, Europe, Australia, and other countries and areas, who did not receive systematic treatment, were included in a study. Results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.

More▼

You can find Sorafenib tosylate suppliers, manufacturers, and distributors from countries such as China, United States and the India here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.

Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd.